Inimmune https://validator.w3.org/feed/docs/rss2.html Team Popup New Shannon Miller, Ph.D. Ferdinand E. Massari, M.D. Helene Bazin-Lee, Ph.D. Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout Ryan McMillian Jon Ruckle, M.D. Mike Sullivan, CPA Medical Chemistry Intern Inimmune to present an Update on Clinical Stage Vaccine Adjuvant and Immunotherapy Programs at the World Vaccine Congress in Washington DC on April 1st Inimmune Announces Successful Phase 1 Clinical Results For Disease Modifying Allergy Treatment, INI-2004 Inimmune to Present at the Medinvest Oncology Conference on INI-4001 Promotion of Th17 polarized immunity via co-delivery of Mincle agonist and Tuberculosis antigen using silica nanoparticles Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems Inimmune Announces First Cancer Patient Dosed in Phase 1 Clinical Study Using the Immunotherapeutic INI-4001, a Novel TLR7/8 Agonist Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1 Insilico Medicine and Inimmune Achieved collaboration to Revolutionize Immunotherapy with AI-Driven Drug Discovery SPI Pharma, Inc. and Inimmune, Corp. Launch Partnership to Commercialize Advanced Adjuvant Systems Inimmune to present successful Phase I allergy trial results at the American Academy of Allergy Asthma & Immunology meeting in San Diego, February 28-March 3, 2025 Inimmune Welcomes Dr. Heather Madsen of Hatteras Venture Partners to Board of Directors Inimmune To Present On Their Next Generation Adjuvants At World Vaccine Congress in Amsterdam In silico discovery and mechanistic profiling of STING agonists engaging the transmembrane domain Inimmune to Showcase Pipeline Advances at World Vaccine Congress 2026 Edwin Kim, MD MS Inimmune participates in the development of an innovative intranasal influenza vaccine Inimmune Commences Pivotal Phase 2 Allergy Trial of INI-2004 in Allergic Rhinitis Patients Inimmune to Present Trial-in-Progress Poster on First-in-Human Study of INI-4001, a Novel TLR7/8 Agonist, at ASCO 2025 Investors David Burkhart, Ph.D. About Cancer Immunotherapy Michael Conger, J.D. Kendal Ryter, Ph.D. Joseph Sulovski Privacy Policy Inimmune to Present Key Updates at the 2025 World Vaccine Congress in Washington, DC April 21-24 Advanced Adjuvant Systems Careers Heather Madsen, Ph.D. elementor-mega-item-4352 Pipeline Allergy Immunotherapy Jay Evans, Ph.D. Leadership Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization Intranasal administration of a novel synthetic TLR4 agonist suppresses allergen-specific Th2 responses in mice A novel immunostimulatory TLR7/8 agonist is curative as a monotherapy in Lewis Lung Carcinoma and synergizes with anti-PD-1 in B16F10 and MC38 tumor models Home